Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Issued (2016 - 2025)

Historic Shares Issued for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $5.8 million.

  • Syndax Pharmaceuticals' Shares Issued rose 12680.45% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 10038.21%. This contributed to the annual value of $8.0 million for FY2024, which is 5600.62% up from last year.
  • According to the latest figures from Q3 2025, Syndax Pharmaceuticals' Shares Issued is $5.8 million, which was up 12680.45% from $468000.0 recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Shares Issued peaked at $162.0 million during Q4 2022, and registered a low of -$69.9 million during Q2 2021.
  • Moreover, its 5-year median value for Shares Issued was $1.9 million (2024), whereas its average is $16.9 million.
  • Examining YoY changes over the last 5 years, Syndax Pharmaceuticals' Shares Issued showed a top increase of 2208934.91% in 2021 and a maximum decrease of 667900.19% in 2021.
  • Syndax Pharmaceuticals' Shares Issued (Quarter) stood at $81.2 million in 2021, then skyrocketed by 99.51% to $162.0 million in 2022, then tumbled by 99.93% to $112000.0 in 2023, then soared by 2702.68% to $3.1 million in 2024, then skyrocketed by 85.19% to $5.8 million in 2025.
  • Its last three reported values are $5.8 million in Q3 2025, $468000.0 for Q2 2025, and $545000.0 during Q1 2025.